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Abstract 
Modeling the natural growth of tumors is of value for evaluation of tumor progression and optimization 
of treatment strategies. However, modeling tumor growth based on clinical data is hampered by the 
limited data available, since therapy is in general initiated as early as possible after diagnosis. Most 
descriptions of tumor growth rate are thus based on two data points per tumor, and assuming 
exponential tumor growth. The time needed for a tumor to double in volume, doubling time (DT), is 
widely used for quantification of tumor growth rate. Growth rate can also be quantified using specific 
growth rate (SGR), equal to ln2/DT. Some studies have shown non-exponential growth characteristics if 
tumors are observed for a relatively long period, usually with a reduced relative growth rate with time. 
Current criteria for evaluation of tumor response to therapy, e.g. RECIST, use change in tumor size as a 
measure and do not consider the natural tumor growth during observation. Knowledge of the natural 
growth model would thus provide a better assessment of therapeutic response. 
In this study, mathematical analyses and computer simulations were used for theoretical evaluation of 
parameters for tumor growth, together with evaluation and application to clinical data. DT and SGR 
were compared for their accuracy as a quantity for tumor growth rate. The relation between growth 
rate and tumor volume was used for estimation of tumor growth model and tumor dissemination rate. 
A general model for tumor response to therapy was developed assuming that an effective treatment 
may decrease the cell proliferation rate (cytostatic effect) and/or increase the cell loss rate (cytotoxic 
effect) of the tumor. 
The results showed that, beside the fact that DT is not defined when two consecutively measured tumor 
volumes are equal, when DT is used for quantification of tumor growth rate, data is transformed to a 
nonlinear scale. This causes an asymmetrical frequency distribution of DT, erroneous estimation of the 
average growth rate, and sometimes contradictory results, compared to SGR. In addition, with limited 
number of tumor volume measurements, curve fitting of different growth models is not sufficient to 
estimate the true growth model. Analysis of the correlation between growth rate and the volume of 
tumor may give better estimate of tumor growth model for some types of tumors. Formation times and 
formation rates of metastases may also be estimated by the linear regression of SGR with the logarithm 
of tumor volume. Furthermore, tumor response was found to be equal to the logarithm of the ratio of 
post-treatment tumor volume to the volume of corresponding untreated tumor. Neglecting the natural 
growth characteristics of tumors results in underestimation of treatment effectiveness using the current 
routine criteria. The presented model may also facilitate integration of data from tumor size changes 
with data from functional imaging, e.g. PET or MRI, for therapeutic efficacy assessment. 
In conclusion, SGR should replace DT for quantification of tumors growth rate. The relation between 
growth rate and tumor volume may facilitate estimation of non-exponential growth characteristics of 
tumors or metastatic dissemination rate. Tumor response to therapy can be assessed with a general 
continuous dimensionless quantity for both cytotoxic and cytostatic agents.  
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Introduction 
Modeling tumor growth 
Modeling the natural (therapy-naive) growth of tumors is of value in the study of tumor 
progression, along with that it will be supportive for optimization of screening programs, 
prognostication (Bassukas, Hofmockel et al. 1996), optimal scheduling of chemotherapy 
(Norton 1988) and radiation therapy, and assessment of tumor spread (number and size 
distribution of metastases, including micro-metastases) (Iwata, Kawasaki et al. 2000; Withers 
and Lee 2006), information that is valuable for targeted radionuclide therapy (Williams, Duda et 
al. 1988; Withers, Peters et al. 1995; Bernhardt, Ahlman et al. 2003). 
 
Tumor response to therapy may also be studied by analyzing the effect of therapy on the 
natural growth of tumor. However, there are mainly two types of growth models for tumors: 
exponential and non-exponential. 
Exponential growth model 
According to the Exponential growth model, tumor volume increases exponentially by time: 
 
,        (1) 
 
where  is the exponential growth constant, and V and V0 are the tumor volume at times t and 
0, respectively. This model implies that the tumor volume can increase indefinitely and the 
growth rate of tumor is proportional to its volume: 
 
αV
dt
dV
        (2)  
 
Tumor volume doubling time (DT) 
Tumor volume doubling time, DT, was introduced for quantification of tumor growth rate in 
1956 when Collins et al. proposed a graphical method to estimate the DT of tumors (Collins, 
Loeffler et al. 1956). DT is the time needed for a tumor to double in volume. The mathematical 
approach for estimation of DT was then proposed in 1961 (Schwartz 1961): 
 
)/Vln(V
)ln2t(t
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where V1 and V2 are two tumor volume estimates at two different occasions, t1 and t2, 
respectively. DT has been widely used as a quantity for tumor growth rate since its 
introduction. There are flaws with DT as a quantity for tumor growth rate: the frequency 
distribution of DT in a population is not normal and there are tumors with very long DT values 
in a population (Spratt 1969). Therefore, mean DT, DTm, does not indicate the average growth 
rate and DT is not suitable for common statistical testing. Some researchers have approximated 
the frequency distribution of DT by a log-normal distribution (Spratt and Spratt 1964; Shackney, 
McCormack et al. 1978; Balmukhanov, Turdugulov et al. 1982; Kuroishi, Tominaga et al. 1990; 
Usuda, Saito et al. 1994). The average growth rate is then estimated by DTlog, calculated as the 
antilog to the arithmetic mean of the logarithms of doubling times (Spratt 1969; Gregory, 
Richards et al. 1991; Spratt, Meyer et al. 1995). The logarithm of DT, log(DT), is also proposed to 
be more suitable for statistical testing (Spratt 1969). DTlog is mathematically equal to geometric 
mean DT, DTgm, which is also used to estimate the average growth rate (Kuroishi, Tominaga et 
al. 1990; Blomqvist, Wiklund et al. 1993; Usuda, Saito et al. 1994).  It is also clear from Eq. 3 
that DT is not defined when the estimated tumor volumes are equal.  The reason for these 
flaws with DT has not previously been studied. 
 
Specific growth rate (SGR) 
From Eq. 2, the exponential growth constant, , is equal to the specific growth rate, SGR, of 
tumor: 
 
dt
dV
V
1
SGR        (4) 
 
SGR is the relative change in tumor volume per unit time, and can be given as percent per unit 
time. For an exponentially growing tumor, SGR is a constant for each tumor, i.e., SGR is 
independent of tumor volume or age. The exponential model can thus be rewritten as 
SGR(t)=SGR0, where SGR0 is the value of SGR at time t0=0. More rapidly growing tumors have 
higher SGR values, SGR=0 represents non-growing tumors, and negative SGR values can be 
assigned to tumor regression. 
 
According to Eq. 1 and Eq. 4, SGR of a tumor can be estimated with two volume measurements 
(V1, V2) at two different occasions (t1, t2): 
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From Eq. 3 and Eq. 5, the relation between SGR and DT is as follows: 
 
SGR
ln2
DT         (6) 
 
However, in the clinics and in clinical studies SGR is not known and tumor growth rate is usually 
quantified using DT. Accuracy of tumor growth rate quantities, SGR and DT, has not previously 
been studied.  
 
Non-exponential tumor growth models 
Studies have shown that tumor growth rate may decline with time (Hart, Shochat et al. 1998; 
Bajzer 1999; Afenya and Calderon 2000), which results in non-exponential growth model of 
tumors. Growth deceleration has been observed in animal models (Wennerberg, Willen et al. 
1988), for solid tumors in clinical studies (Spratt, von Fournier et al. 1993; Spratt, Meyer et al. 
1996), and in leukemia (Afenya and Calderon 2000). Growth deceleration is attributed to 
several factors, including prolonged cell cycle, reduced growth fraction, decreased availability 
of oxygen (Pavelic, Porter et al. 1978), decreased cell proliferation rate with increased cell loss 
rate (Bassukas and Maurer-Schultze 1987), tumor-related systemic factors (DeWys 1972), and 
allometric growth control (Prehn 1991). A number of non-exponential growth models are 
available in the literature, among which the Gompertzian model is widely used (Araujo and 
McElwain 2004). 
 
The Gompertzian model 
According to the Gompertzian growth model, the variation of tumor volume by time is as 
follows (Marusic, Bajzer et al. 1994; Afenya and Calderon 2000): 
 
 ,      (7) 
 
where  is comparable with the growth constant in the exponential model, i.e. SGR at t=o, and 
λ is a constant for growth retardation. The Gompertzian model decreases to the exponential 
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model (Eq. 1) when λ approaches zero (λ→0). According to the Gompertzian model, the tumor 
cannot grow indefinitely, but asymptotically approaches a maximum equal to , when t→∞. 
 
Tumor growth model in clinical studies 
The basic method to find the growth model of tumors is by direct curve fitting. Using this 
method, different growth model equations are fitted to the volume of each individual tumor 
and the model with the best fitting can be selected. In clinical studies, where the natural 
growth of tumor can be followed for a limited period, the exponential model is usually used to 
describe the growth of tumors. Proposals for new quantitative approaches to analyze tumor 
growth models in clinical settings are thus needed.  
 
The SGR of different tumor types or even metastases of the same type, in the same patient, and 
in the same tissue are not necessarily the same. The variation of SGR among the tumors can be 
a result of biological differences between tumors, or growth retardation. If the growth model of 
tumors is the Gompertzian then larger tumors will have lower SGR values and vice versa. From 
Eq. 7, the relation between SGR and tumor volume is as follows: 
 
      (8) 
 
Eq. 8 shows that SGR decreases linearly by the logarithm of tumor volume if the growth model 
is Gompertzian. Eq. 8 does not include time, which makes it possible to use data from tumors 
without the knowledge of the age of each tumor. The feasibility of estimating the non-
exponential growth parameter of tumors, i.e. λ in Eq. 7-8, based on growth rate relation with 
tumor volume needs to be investigated.  
 
Tumor response to therapy 
Assessment of tumor response to therapy is necessary for evaluation of the efficacy of novel 
anticancer drugs in clinical trials. It may also be valuable in individualized therapy rather than 
standardized treatment regimen in daily clinical practice. Traditional anticancer agents exhibit 
cytocidal effect by actively destroying tumor cells and, therefore, tumor shrinkage has been 
used as measure of treatment efficacy. 
 
Response Evaluation Criteria in Solid Tumors (RECIST) 
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The Response Evaluation Criteria in Solid Tumors (RECIST) is currently adopted by academic and 
industrial groups (Miller, Hoogstraten et al. 1981; Therasse, Arbuck et al. 2000), where 
response to therapy is categorized as follows: Complete response (CR): the disappearance of all 
target lesions; Partial response (PR): at least a 30% decrease in the sum of the longest diameter 
of target lesions; Progressive disease (PD): at least a 20% increase in the sum of the longest 
diameter of target lesions or the appearance of one or more new lesions; Stable disease (SD): 
neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for 
progressive disease (Therasse, Arbuck et al. 2000). Appropriateness of RECIST criteria, e.g. 
whether the change in tumor size is a proper endpoint for response assessment, has been 
widely discussed (Barnacle and McHugh 2006; Tuma 2006; Twombly 2006; Eisenhauer 2007).  
 
Limitations of RECIST 
The following four limitations can be identified in the RECIST criteria: 
 
Firstly, the idea behind RECIST is that a treatment regimen is effective if the tumor size is 
reduced. However, there are emerging numbers of anticancer drugs, which inhibit tumor 
growth rather than actively destroy tumor cells. Traditional response evaluation criteria, 
including RECIST, may not be appropriate to assess the efficacy of such cytostatic agents, which 
do not result in tumor regression to a point of PR or CR. General means of assessment of both 
cytocidal and cystostatic effects must, therefore, be developed (Michaelis and Ratain 2006; 
Gwyther and Schwartz 2008). 
 
Secondly, the natural growth rate of tumor is not considered in RECIST. A certain treatment 
that kills the same relative amount of tumor cells in two different tumor types will give 
different results, according to RECIST, if the natural proliferation rates of tumor cells are 
different. 
 
Thirdly, adopting the RECIST criteria will convert a continuous variable, as tumor response, into 
a discrete variable; resulting in loss of information. This will make comparison of individual, or 
combination of, treatments less accurate. Furthermore, attempts to relate treatment efficacy 
to molecular or cellular characteristics of tumors, e.g. by systems biology approach, will be 
difficult when data is categorized.  
 
Fourthly, many studies have shown that the effect of treatment on tumors can be assessed by 
means of changes in tumor characteristics other than size, e.g., estimated by positron emission 
6 
 
tomography (PET) or magnetic resonance imaging or spectroscopy (MRI/MRS). RECIST does not 
accommodate integration of physiological or functional imaging parameter into anatomical 
changes in tumor, and, therefore, new methods must be developed (Jaffe 2008). 
 
The log-ratio (LR) method 
Karrison et al. (Karrison, Maitland et al. 2007), based on suggestions by Lavin et al. (Lavin 1981), 
demonstrated that clinical trial designs that treat change in tumor size as a continuous variable 
rather than categorizing the changes are feasible (Karrison, Maitland et al. 2007). They used the 
logarithm of the ratio of tumor volume after therapy to that at baseline as a continuous end-
point for quantification of tumor response, denoted as LR (log-ratio) (Karrison, Maitland et al. 
2007).  
 
Limitation of LR method 
The main flaw with LR method is that the natural growth of tumor between measurement at 
baseline and therapy initiation and also during therapy is neglected. 
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Aims 
The aims of this work were 
 
1) To determine an accurate quantity for tumor growth rate. (Papers I, II) 
 
2) To develop a method for estimation of tumor growth rate and dissemination rate in clinical 
settings. (Paper III) 
 
3) To develop a general measure for assessment of tumor response to therapy, where the 
natural tumor growth rate is taken into account. (Paper IV) 
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Material and Methods 
Quantitative analysis of tumor growth and dissemination 
SGR versus DT: influence of measurement uncertainties (paper I) 
To determine the most accurate quantity for tumor growth rate, equivalent doubling time, DTe, 
was compared to DT. DTe is DT calculated for mean SGR in a population. DT, log(DT), and SGR, 
the frequency distribution of these parameters and variation of their means, DTm, DTlog, and 
DTe, were analyzed by computer simulations and  clinical data. 
 
Monte Carlo simulations 
Computer simulations were done using a Monte Carlo code, written in visual basic 6.0 
(Microsoft, USA), for typical values of measurement time interval and DT (Table 1) (Rew and 
Wilson 2000).  
 
For each time interval 105 simulations were done. In each simulation, V1 and V2 were generated 
and SGRi and DTi were estimated for the range of i indices 1-10
5. For each time interval, DTm, 
DTlog, mean SGR (SGR ), and DTe were calculated, where  
100000/)SGR...SGR(SGRSGR 10000021    (9) 
and 
SGR/ln(2)DTe  .      (10) 
The relative uncertainty of SGR )SGR σ( SGR  was calculated and compared to the expected 
uncertainty calculated from Eq. 4, which can be rewritten as   )t/(t)ln(V)ln(VSGR 1212  , giving 
)t/(t)/V(σ)/V(σ)t/(tσσσ 12
2
22V
2
11V12
2
2lnV
2
1lnVSGR  .   (11) 
If both sides of the above equation are divided by SGR and SGR on the right side is replaced 
from Eq. 5, then: 
2
22V
2
11V12SGR )/V(σ)/V(σ)}t{DT/(t2)/ln(1/SGRσ  .  (12) 
Since DT is inversely proportional to SGR, the simulation will generate unstable results for SGR 
close to zero. Therefore, SGR values between -0.0000693 and +0.0000693, corresponding to DTi 
with absolute values longer than 10000 days, were excluded from the calculations.  
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Since the logarithm of negative and zero values are undefined, the following method was used 
in the calculation of DTlog in the presence of negative DTi values: the absolute value of the 
minimum possible DT (-10000) plus one, i.e. 10001, was added to all DT values, and the mean of 
their logarithms was calculated. Thereafter, DTlog was derived by subtracting 10001 from the 
obtained mean value. To investigate how the exclusion of negative growth rate values can 
influence the average growth rate estimators, DTm, DTlog, and DTe, the simulation was then 
repeated excluding SGR values less than +0.0000693. 
 
Clinical data 
DTm, DTlog, and DTe were calculated for several types of tumors using quantitative data from 
previously published clinical studies (Table 1)(Blomqvist, Wiklund et al. 1993; Saito, Matsuzaki 
et al. 1998; Nishida, Kaneko et al. 1999; Wang, Sone et al. 2000; Furukawa, Iwata et al. 2001; 
Nakajima, Moriguchi et al. 2002; Winer-Muram, Jennings et al. 2002; El Sharouni, Kal et al. 
2003). The results were then compared with computer simulations. 
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SGR versus DT regardless of measurement uncertainties (paper II) 
 
Variation of DT per unit SGR 
According to Eq. 6, the variation of DT with SGR is: 
 
2SGR
ln(2)
ΔSGR
ΔDT
        (13) 
 
Table 1) Clinical data on tumor growth obtained from the literature. W, M, and P denote well, moderate, and 
poorly differentiated, respectively. n=number of tumors 
Study Tumor 
Measurement 
time interval 
(d) 
Doubling 
time range 
(d) 
n Reference 
1 Pancreatic carcinoma Not published 18-232 12 (Nishida, Kaneko et al. 1999) 
2 Pancreatic carcinoma 99-751 64-255 9 (Furukawa, Iwata et al. 2001) 
3 Adenocarcinoma (lung) 159-396 72-131 8 (Wang, Sone et al. 2000) 
4 Adenocarcinoma (lung) 25-1212 (-1350)-964 15 (Winer-Muram, Jennings et al. 2002) 
5 Bronchioalveolar (lung) 39-973 36-1092 9 (Winer-Muram, Jennings et al. 2002) 
6 Squamous cell lung carcinoma 43-536 (-1214)-225 16 (Winer-Muram, Jennings et al. 2002) 
7 Non small cell lung carcinoma 82-948 48-698 6 (Winer-Muram, Jennings et al. 2002) 
8 Non small cell lung cancer 16-99 8-171 18 (El Sharouni, Kal et al. 2003) 
9 Small cell lung cancer 299-386 54-132 4 (Wang, Sone et al. 2000) 
10 Sarcoma (lung metastases) 14-819 7-1172 21 (Blomqvist, Wiklund et al. 1993) 
11 Hepatocellular carcinoma (W) 43-252 38-274 19 (Nakajima, Moriguchi et al. 2002) 
12 Hepatocellular carcinoma (W) 63-763 76-720 15 (Saito, Matsuzaki et al. 1998) 
13 Hepatocellular carcinoma (M) 13-224 17-91 9 (Nakajima, Moriguchi et al. 2002) 
14 Hepatocellular carcinoma (M) 91-210 94-380 6 (Saito, Matsuzaki et al. 1998) 
15 Hepatocellular carcinoma (P) 20-182 20-78 6 (Nakajima, Moriguchi et al. 2002) 
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It shows that the variation of DT per unit SGR is not constant for the whole range of SGR; it 
quickly decreases with increasing the absolute value of SGR. Variation of DT per unit SGR was 
plotted for SGR values between -5 %/d and +5 %/d, corresponding to DT values of -14 days to -
∞ and 14 days to +∞, respectively. 
 
Clinical data 
Two examples from previously published articles were found that could represent the 
difference between the results of statistical analyses based on DT and SGR. In the first study, 
the authors found statistically significant difference between DT of prostate specific antigen 
(PSA) before and after treatment in each of 9 out of 12 patients (Guess, Jennrich et al. 2003). 
Using the signed rank test, they could also detect a significant positive shift in the frequency 
distribution of DT after treatment. In the present study, increase rate of PSA before and after 
treatment was compared in 12 patients using DT as well as SGR of PSA by student’s t-test (Table 
2). (Note: The authors of the original article used a method to study PSA level variations in each 
patient, while in the current study the PSA change in the group of patients was studied). In the 
second example, the authors examined the DT of serum CA 19-9 in patients with pancreatic 
cancer (Nishida, Kaneko et al. 1999). A significant correlation was found between the DT of the 
serum level of CA 19-9 and the DT of tumor volume in 11 out of 75 patients, where both DT 
values were available. In the present study, the corresponding SGR values of the DT of tumor 
marker as well as the DT of tumor volume were calculated (Table 3) and the correlation 
between the two variables was examined. 
 
Analysis of tumor growth in clinical settings (paper III) 
Clinical data 
Data from population studies 
Data from clinical studies were retrieved from the literature based on the availability of tumor 
volume estimates and corresponding measurement time intervals. Correlation between the 
growth rate and the volume of tumor was calculated for the following types of tumors: 
meningioma (Nakamura, Roser et al. 2003; Nakasu, Fukami et al. 2005), hepatocellular 
carcinoma (Saito, Matsuzaki et al. 1998; Nakajima, Moriguchi et al. 2002; Taouli, Goh et al. 
2005), pancreatic carcinoma (Furukawa, Iwata et al. 2001), and primary lung cancer (Wang, 
Sone et al. 2000). 
Data from individual patients 
The first patient was diagnosed with primary midgut carcinoid and liver metastases. The 
primary tumor was surgically resected in 1995. Growth data were obtained from 8 CT 
examinations performed annually during 1995-2002. During this period the patient was treated 
with octreotide (Sandostatin, Sandoz/Novartis, Basel, Switzerland) for hormonal symptom 
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relief, and interferon alfa-2b (IntronA, Schering-Plough Corporation, New Jersey, USA) was 
given at three occasions without clinical response. The volume of each tumor was measured by 
point counting: a transparent paper with square millimeters was used to measure the tumor 
area in CT slices and the tumor volume in the slice was estimated by multiplying the tumor area 
and the slice thickness. The total volume of the tumor was calculated as the sum of tumor 
volumes from the different CT slices.  
 
The second patient was diagnosed with primary renal cell carcinoma with lung metastases. The 
growth of 7 lung metastases in this untreated patient was studied. A total of 32 conventional 
two-dimensional AP chest radiographs from the patient were available from 1989 to 1999. The 
area of each tumor in each radiograph was then estimated using Osiris (cf. 
http://www.sim.hcuge.ch/osiris/01_Osiris_Presentation_EN.htm). Each tumor was assumed to 
be equal to the volume of a sphere with the diameter of a circle with the same area as the 
estimated tumor area in the radiograph. Since the lining border of the tumor could not be 
clearly defined in all images, the number of available data points may be different for different 
metastatic tumor masses. 
 
Direct curve fitting 
The exponential (Eq. 1) and the Gompertzian (Eq. 7) growth curves were fitted to the volume of 
any metastases in individual patients. The curve fittings were performed using Matlab 6.5.1 
with the curve fitting toolbox (The MathWorks, USA). 
 
SGR deceleration analysis 
Correlation between tumor growth rate and its volume for each group of tumors was studied as 
follows. (1) SGR values were calculated according to Eq. 5 for each pair of consecutive tumor 
volume measurements. (2) Each SGR value was assigned to the geometric mean of the two 
volumes. (3) Correlation between SGR and the logarithm of tumor volume was calculated for all 
SGR values for the same tumor type in a population or for the same type of metastasis in the 
same host tissue in the same patient.  
 
The relatively large number of tumors in one of the meningioma studies (Nakamura, Roser et 
al. 2003) enabled us to draw the frequency distribution of tumors in small (< 6 cm3) and large 
(>6 cm3) groups and compare SGR between the groups using Student’s t-test. 
 
Metastasis formation rate estimations 
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For data from individual patients (two cases), the analysis was continued as follows. (1) 
Assuming V0=10
-9 cm3 (one cell), Eq. 7 with parameters obtained from the regression line 
between SGR and the logarithm of tumor volume was assumed to represent the general 
Gompertzian growth model of the metastases (with variable formation time). Formation time 
of each tumor was obtained by the best fitting of the general growth model to the volume of 
the tumor. (2) Formation time of the earliest metastasis was set to zero and the number of 
metastases as a function of time after formation of the first metastasis was obtained. (3) To 
study the applicability of the standard curve fitting method, the exponential and the 
Gompertzian curves were fitted to the growth of each tumor and the best fits were estimated. 
The metastasis formation rate was calculated as above according to the best exponential fit to 
each tumor.  
 
Modeling tumor response to therapy (paper IV) 
 
Kinetics of tumor growth 
Eq. 5 can be used to estimate the SGR of tumors at any time period. If SGR is time dependent, 
as for non-exponentially growing tumors, Eq. 5 can be rewritten as follows: 
 
 ,      (14) 
 
where SGR(t) is the SGR at time t. The value of SGR(t) depends on the level of cell proliferation 
rate, CPR(t), and cell loss rate, CLR(t), at time t: 
 
      (15) 
 
Tumor response to therapy (TR) 
If the natural growth of tumor is interrupted by therapy, an effective therapeutic agent may 
increase the CLR (cytotoxic effect) and/or decrease the CPR (cytostatic effect) of tumor. An 
effective treatment will thus decrease SGR to SGR′ regardless of the mechanism of the 
therapeutic effect:  
 
ΔSGR(t)-SGR(t)(t)RSG  ,     (16) 
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where ΔSGR(t) is the effect of treatment at time t. Temporal variation of SGR′ depends on all 
factors that naturally affect tumor growth as well as the effect of therapy. Readjustment and 
integration of the above equation over time gives: 
 
dt(t)SGR'dtSGR(t)dtSGR(t)Δ
t
t
t
t
t
t i ii
    ,  
 
where ti and t are the time of therapy initiation and efficacy assessment, respectively. The right 
side of the above equation can be replaced using Eq. 14, which gives: 
 
)
V
V
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V
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ln(dtSGR(t)Δ
i
t
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n
t
ti
 , 
 
where Vi is tumor volume at time of therapy initiation, and Vt and Vn are the volume of treated 
and corresponding (hypothetical) non-treated tumor at time of efficacy assessment, 
respectively. The left side of the above equation is the overall effect of treatment during time 
from treatment initiation to time of efficacy assessment, and can be denoted as TR (tumor 
response). Since ln(Vn/Vi)-ln(Vt/Vi)=-ln(Vt/Vn): 
 
        (17) 
 
Based on the above equation, TR is a general continuous dimensionless quantity for tumor 
response to both cytotoxic and cytostatic therapeutic effects. TR can thus be calculated by the 
logarithm of the ratio of post-treatment volume of tumor to the volume that the tumor would 
have (at time of efficacy assessment) if the growth was not interrupted by therapy. The value of 
Vn can be estimated having the natural growth model of tumor.  
 
Eq. 17 was transformed by replacing Vn with the following assumptions: (1) Tumor volume at 
first diagnostic investigation is Vd; (2) therapy is initiated ∆tpre days after measurement of Vd; (3) 
tumor grows exponentially with SGR(t)=SGR0 during this period and tumor volume at time of 
therapy initiation is Vi; (4) tumor response is assessed ∆tpost days after therapy initiation and 
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tumor volume at time of efficacy assessment is Vt;  (5) tumor would continue to grow with SGR0 
if the growth was not interrupted and its volume would be Vn at time of efficacy assessment. 
 
Non-Hodgkin’s lymphoma patients treated with 131I labeled anti-B1 antibody 
TR values were calculated for treatment of non-Hodgkin’s lymphoma patients with 131I labeled 
anti-B1 antibody, where data was from a previously published article (Sgouros, Squeri et al. 
2003). The study was selected based on the availability of tumor volumes and the time of pre- 
and post- treatment volume estimations in each patient: information which is necessary for TR 
calculation. Total tumor burden was assessed by drawing contours around all lymphoma lesions 
identified on whole-body CT or MRI. Variations of total tumor burden in 11 patients before and 
after treatment were estimated from figure 2 in the original article (Sgouros, Squeri et al. 2003). 
Two more patients are included in the original article, where tumors disappeared after 
treatment. Those data were excluded in the present study. To estimate the natural growth rate 
of Non-Hodgkin’s lymphomas in the present study the average post-treatment re-growth rate 
of 5 tumors  was used. 
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Results 
Tumor growth and dissemination 
SGR versus DT: influence of measurement uncertainties (paper I) 
Monte Carlo simulations 
Figure 1 shows the simulated frequency distributions of DT (panel A), log(DT) (panel B), and SGR 
(panel C) for different time intervals (1, 5, 10, 50, 100, and 200 days), when the relative 
uncertainty of the volume measurement was 10%. For a time interval of 200 days (2 DTtrue), all 
DT values were positive and the frequency distribution of DT was symmetric and centered at 
DT=100 days (Fig. 1A). When the time interval was 100 days (1 DTtrue) the frequency distribution 
of DT was positively skewed and the peak shifted towards lower DT values. When the time 
interval was 50 days (0.5 DTtrue) the peak shifted more towards lower DT values and negative 
DT values appeared in the data as a very small peak in the negative range. The peak in the 
negative range increased further with decreasing time interval. With a 1 day time interval the 
two peaks were very close and symmetric in relation to zero and appeared as a single peak 
centered at zero (Fig. 1A).  Therefore, mean DT was close to zero for very short time intervals. 
Theoretically, when the time interval approaches zero the position of two peaks asymptotically 
approaches zero with a height of infinity. If negative values of DT were excluded, the peaks on 
the negative side of the frequency distribution of DT disappeared. Variations in the frequency 
distribution of log(DT) (Fig. 1B) were comparable to that of DT. For the time intervals of 200 and 
100 days all DT values were positive and only one peak appeared in the frequency distribution 
of log(DT) centered at 4.6 (=log 100) for 200 days and slightly shifted to the left for 100 days. 
For shorter time intervals, where negative DT values appeared in data, the peak shifted more to 
lower values in relation to 4.6, when negative DT values were excluded (Fig. 1B). When negative 
DT values were included for 50, 10, and 1 day time intervals the symmetry point was shifted to 
9.21 (=log 10001), see Materials & Methods, comparable to zero in the frequency distribution 
of DT (Fig. 1B-insert b). For a 1 day time interval the two peaks looked like a single peak 
centered at 9.21.  Therefore, also DTlog was close to zero for very short time intervals (Fig. 2).  
The frequency distribution of SGR was symmetric for all time intervals studied. The mean SGR 
was equal to the true SGR (0.7 %/d) and its uncertainty increased with decreased time interval. 
The expected uncertainty of SGR from Eq. 12 and the calculated uncertainty of SGR from the 
simulations were well correlated (R2>0.999). 
 
The results of the computer simulations of DTm, DTlog, and DTe are shown in Figure 2. When the 
time interval was very long compared to DTtrue, all DT estimators were equal to DTtrue of the 
tumor (Fig. 2A). When the time interval decreased, DTm overestimated DTtrue with a maximum 
deviation of about 30%. For very short time intervals compared to DTtrue, DTm underestimated 
DTtrue and approached zero for time intervals down to a few days. DTlog showed a similar 
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variation as DTm, with a maximum overestimation of about 20%, but a larger underestimation 
than DTm for short time intervals. Neglecting small fluctuations at very short time intervals, DTe 
was equal to DTtrue for all time intervals studied (Fig. 2A). When the negative growth rate values 
were excluded, DTm and DTlog followed a similar shape as when the negative values were 
included (Fig. 2B), i.e., overestimation up to a maximum and then decreasing with decreasing 
time interval. However, the ranges of deviation from DTtrue were different. When negative 
values were excluded DTm was much higher, while DTlog was closer to when negative values 
were included. Furthermore, DTe decreased with decreasing time interval and was lower than 
DTlog, which in turn was lower than DTtrue when negative values were excluded. Then, DTe 
approached zero for very short time intervals down to a few days. 
 
 
 
 
Figure 1) Simulated frequency distributions of A) DT, B) log(DT), and C) SGR at measurement time 
intervals from 1 to 200 days. The relative uncertainty of volume estimation was 10% and the true 
DT was 100 days. For 50, 10, and 1 day measurement time intervals, negative DT values were 
excluded for panel B, while included for the insert b and panels A and C. Note the different scales 
of the y-axes of all panels, and the different scales of the x-axes of Figure 2B.  
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Clinical data 
DTm, DTlog, and DTe values estimated from the previously published clinical data on several 
types of tumors are presented in Figure 3. The measurement time intervals varied between 13 
and 1212 days. The estimated doubling times from these papers were between -1350 and 1172 
days. The only study containing negative growth rates was that of adenocarcinoma and 
squamous cell lung carcinoma (31). For all studies including only positive growth rates, DTe was 
lower than DTlog, which was lower than DTm (Fig. 3A). On average, DTlog and DTm were 25% 
(range 3-88%) and 76% (range 6-317%) higher than DTe, respectively.  If the negative growth 
rates were included, negative DTm was obtained, while DTe was still positive (data not shown). 
 
The SGR values from clinical data are summarized in Fig. 3B. Since SGR and DT are reciprocally 
related (Eq. 6), a higher SGR value in Fig. 3B corresponds to a shorter DTe in Fig. 3A and vice 
versa. Such trend was not always seen for DTm and DTlog values, since they may over- or 
underestimate the true DT of tumors depending on volume measurement uncertainties and the 
time interval.  
 
 
 
Figure 2) Simulated results of DTm, DTlog, and DTe for maximum 10% volume measurement uncertainty and 
different measurement time intervals. The true DT value was 100 days. Negative values of growth rate were 
included in panel A and excluded in panel B. For proper scaling of the DT axis and clear presentation of 
deviations from true DT, DTm values of 454, 471, and 776 at 28, 20, and 14 days time intervals were excluded 
from panel B, respectively. 
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SGR versus DT regardless of measurement uncertainties (paper II) 
Variation of DT per unit SGR 
Figure 4 shows the variation of DT per 1 %/d change in SGR based on Eq. C. Each %/d of SGR 
corresponds to a change in DT of 3 days when the SGR is ±5 %/d. With decreasing the absolute 
value of SGR, each %/d change of SGR corresponds to a higher value on the DT scale, with 69 
days at ±1 %/d and approaching infinity at SGR=0. A DT of 1 day does not represent the same 
growth rate when the tumor is slowly growing as when the tumor is rapidly growing (Fig. 4). For 
a slowly growing tumor with low SGR, DT increases considerably with a slight decrease in SGR. 
For a rapidly growing tumor with high SGR, DT decreases slightly even with a large increase in 
SGR. DT understates the growth rate of slowly growing tumors and overstates the growth rate 
of rapidly growing tumors. 
 
Figure 3) A) DTm, DTlog, and DTe and B) SGR values determined from previously published clinical data. 
Numbers in brackets show the study number according to Table 1. Abbreviations: PC: pancreatic carcinoma 
(Nishida, Kaneko et al. 1999; Furukawa, Iwata et al. 2001). Primary lung cancers: ADN: adenocarcinoma 
(Wang, Sone et al. 2000; Winer-Muram, Jennings et al. 2002), BAC: bronchioalveolar (Winer-Muram, Jennings 
et al. 2002), SCC: squamous cell carcinoma (Winer-Muram, Jennings et al. 2002), NSC: non-small cell 
carcinoma (Winer-Muram, Jennings et al. 2002), NSCLC: non-small cell lung cancer (El Sharouni, Kal et al. 
2003), SCLC: small cell lung cancer (Wang, Sone et al. 2000). MLC: metastatic lung cancer from bone and soft 
tissue (Blomqvist, Wiklund et al. 1993). HCC: hepatocellular carcinoma (Saito, Matsuzaki et al. 1998; Nakajima, 
Moriguchi et al. 2002). W, M, and P denote well, moderate, and poorly differentiated tumors, respectively.  
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Clinical data 
For the clinical studies, the difference between DT of PSA level before and after treatment was 
not statistically significant (p>0.1), but the difference between SGR of PSA level before and 
after treatment was statistically significant (p<0.002) (Table 2). In addition, the correlation 
Table 2) Increase rate of PSA level before and after treatment initiation. DT values were retrieved from a 
previously published clinical study, Guess et al. (2003) (Guess, Jennrich et al. 2003), and the corresponding SGR 
values were calculated (Eq. 6). The difference between DT of PSA level before and after treatment is not 
statistically significant (p>0.1). The difference between SGR of PSA level before and after treatment is 
statistically significant (p<0.002). Note: Patient ID is the same ID used in the original paper. 
PatientID 
DT (months) SGR (%/month) 
Before treatment After treatment Before treatment After treatment 
3 3.97 13.43 17.46 5.16 
7 5.67 10.11 12.22 6.86 
8 1.14 2.91 60.80 23.82 
9 3.37 7.71 20.57 8.99 
11 1.58 16.49 43.87 4.20 
13 10.5 7.97 6.60 8.70 
15 2.66 11.95 26.06 5.80 
17 3.64 3.27 19.04 21.20 
18 2.04 4.96 33.98 13.97 
20 2.33 3.24 29.75 21.39 
21 6.29 -155.49 11.02 -0.45 
22 5.12 -645.51 13.54 -0.11 
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Figure 4) Change in DT per %/d change in SGR, dDT/dSGR, versus SGR. dDT/dSGR changes slightly for rapidly 
growing tumors, whereas it changes largely for slowly growing tumors and approaches ∞ when SGR 
approaches zero, i.e., DT approaches ∞. 
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between DT of CA 19-9 level and DT of tumor volume was statistically significant (p<0.0001), 
but the correlation between SGR of CA 19-9 and SGR of tumor volume was not statistically 
significant (p>0.3) (Table 3). 
 
 
 
Analysis of tumor growth in clinical settings (paper III)  
Tumors growth deceleration in the population data 
The correlation between SGR and the logarithm of the volume was statistically significant for 
one study on meningiomas (Nakamura, Roser et al. 2003) and was not statistically significant 
for any of the other studies (Table 4). The difference between the growth rates of the large and 
small meningioma tumors with significant SGR deceleration was statistically significant 
(p<0.001), with higher SGR for smaller tumors (Fig. 6). 
Table 3) Growth rate of tumor volume as well as the increase rate of serum CA 19-9 in 11 patients with 
pancreatic cancer. DT values were retrieved from a previously published clinical study, Nishida et al. 
(1999) (Nishida, Kaneko et al. 1999), and the corresponding SGR values were calculated (Eq. 6). The 
correlation between DT of CA 19-9 level and DT of tumor volume is statistically significant (p<0.0001). 
The correlation between SGR of CA 19-9 and SGR of tumor volume is not statistically significant (p>0.3). 
Note: Patient no. is the case number used in the original paper. 
Patient 
no. 
CA 19-9 DT 
(d) 
Tumor DT 
(d) 
CA 19-9 SGR 
(%/d) 
Tumor SGR 
(%/d) 
2 8.3 34.8 8.4 2.0 
6 39.7 44.6 1.7 1.6 
9 46.3 34.5 1.5 2.0 
26 36.5 21.2 1.9 3.3 
35 30.4 47.7 2.3 1.5 
36 67.1 112.8 1.0 0.6 
40 44.7 70.6 1.6 1.0 
47 24.7 18.4 2.8 3.8 
50 42.7 50.6 1.6 1.4 
62 137.5 231.6 0.5 0.3 
68 42.3 39.3 1.6 1.8 
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Tumors growth models in individual patients 
For the patient with liver metastases from a primary midgut carcinoid and the patient with lung 
metastases from a primary renal cell carcinoma, it was possible to examine direct curve fitting 
for most tumors, because the tumors had been followed for relatively long periods: up to 7 and 
10 years, respectively. The volume of each tumor in the liver (except for two metastases), or in 
the lungs, could be well described either by the exponential or by the Gompertzian model. The 
two metastases in the liver were only observed at two occasions, and the Gompertzian model 
requires three data points for curve fitting. Based on the results of the direct model fitting it 
was not possible to select the most probable growth model of each tumor. However, the 
estimated tumor formation times and SGR0 values were different when estimated by the 
different models. The estimated formation time of one of the tumors in the liver, obtained by 
the exponential fit, was not realistic (5 years before the birth of the patient). For the best 
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Figure 6) Frequency distribution of SGR in two groups of small (n=20) and large (n=21) 
meningioma tumors, based on data from reference (Nakamura, Roser et al. 2003). 
Mean SGR was 20 %/y and 6 %/y for small and large tumors, respectively. 
 
Table 4) Correlation between the specific growth rate, SGR, and the logarithm of tumor volume in groups 
of patients diagnosed with the same type of tumor. n: number of tumors. r: correlation coefficient. NS: not 
statistically significant 
Tumor type (reference) n r
2
 r p-value 
Meningiomas (Nakamura, Roser et al. 2003) 41 0.2424 -0.4923 <0.01 
Meningiomas (Nakasu, Fukami et al. 2005) 36 0.0104 -0.1020 NS 
Hepatocellular carcinoma (Nakajima, Moriguchi et al. 2002) 34 0.0380 0.1949 NS 
Hepatocellular carcinoma (Saito, Matsuzaki et al. 1998) 21 0.0134 -0.1158 NS 
Hepatocellular carcinoma (Taouli, Goh et al. 2005) 16 0.0014 -0.0374 NS 
Pancreatic carcinoma   (Furukawa, Iwata et al. 2001) 9 0.0041 -0.0640 NS 
Primary lung cancer (Wang, Sone et al. 2000) 12 0.1619 -0.4024 NS 
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exponential fits the SGR values were 0.14-0.33 %/d. These values correspond to DT values of 7-
17 months. 
 
Figure 7 shows the best exponential and Gompertzian model curve fits for the volume of the 
largest metastasis in the liver. It shows that the two models could fit well with the volume of 
tumor in a short time interval, whereas the extrapolated formation times of tumor differ 
widely: 1947 and 1982 with the exponential and Gompertzian models, respectively. The 
estimated SGR at time of formation of tumor (SGR0) was also largely different: 0.14 %/d and 1.1 
%/d with the exponential and the Gompertzian models, respectively. These values correspond 
to DT values of 17 months and 2 months, respectively. 
 
 
The negative correlation between SGR and the logarithm of tumor volume was statistically 
significant (r2=0.33, p<0.005) for the liver metastases, and the estimated λ and SGR0 values 
were 0.00023 and 0.79 %/d, respectively. Curve fitting of the general Gompertzian growth 
model to data for the liver metastases are shown in Fig. 8. The same growth curve is shifted in 
time to fit the volume of each tumor. 
 
For the patient with lung metastases, the SGR values for the best exponential fits were 0.14-
0.39 %/d. These values correspond to DT values of 6-17 months, respectively. 
For this patient the negative correlation between SGR and the logarithm of tumor was not 
statistically significant. The estimated λ and SGR0 values were 0.00007 and 0.46 %/d, 
respectively. However, the general Gompertzian growth model based on these parameters 
 
Figure 7) The best exponential (dashed line) and Gompertzian (solid line) model curve fits to the logarithm of 
the volume of metastasis A in the liver with extrapolation to the volume of one cell. b is the birth of patient. 
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could be fitted to data from each metastasis in the patient. The same growth curve could be 
shifted in time to fit the volume of each tumor, as for liver metastases (Fig. 8). 
 
Metastasis formation rates in individual patients 
Figure 9 shows the number of metastases as a function of time in each patient. The number of 
metastases increased exponentially by time assuming that the tumors grow either 
exponentially with different growth rates or according to a general Gompertzian model. The 
increase rate of the number of metastases based on the Gompertzian model was higher than 
the rate based on the exponential model. 
 
 
 
 
Figure 9) The number of metastases vs. the time from formation of the first metastasis. The metastasis 
formation rates were determined for the metastases in the liver and the lungs according to the exponential 
and Gompertzian growth models. Values in parentheses show the constant of exponential increase rate (y
-1
). 
 
Figure 8) The logarithm of the tumor volume vs. time for all metastases in the liver with the general 
Gompertzian growth model curve fits. 
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Tumor response model (paper IV) 
General tumor response model for exponentially growing tumors 
When the tumor response model developed in the present study (Eq. 17) is applied to an 
exponentially growing tumor, TR is related to tumor volume and growth rate as follows (Fig. 
10): 
 
 .   (18) 
 
The first term on the right hand side of the above equation, LR, is the treatment effectiveness 
where the natural growth of tumor is neglected and is equivalent to the log ratio (LR) measure 
suggested by Kharison et al. (Karrison, Maitland et al. 2007). LR values less than -0.5, between -
0.5 and +1, and larger than +1 correspond to progressive disease, stable disease, and partial 
response according to RECIST, respectively. The second term, e1, and the third term, e2, 
represent tumor growth prior to and after treatment initiation, respectively. The overall effect 
of tumor growth from time of diagnosis to time of efficacy assessment, ∆t, sums up as follows: 
 
     (19) 
 
The above equation indicates that evaluation of treatment effectiveness by comparing the 
volume of treated tumor with pre-treatment tumor volume underestimates the effect of 
therapy by Err.  
 
Tumor response to pure cytostatic effect 
If a therapeutic drug has pure cytostatic effect, i.e., the drug inhibits tumor growth, but does 
not destroy existing tumor cells, and if the drug can completely block tumor growth, the tumor 
volume at time of efficacy assessment will be the same as the tumor volume at time of 
treatment initiation, Vi. The cytostatic efficacy of treatment is then e2=ln(Vn/Vi)  (Fig. 10). If the 
drug can partially control tumor growth, the tumor volume at time of efficacy assessment will 
be larger than Vi (closer to Vn) and the treatment efficacy will be less than e2 in Fig. 10. Note 
that tumor volume at time of efficacy assessment is, however, larger than tumor volume at 
time of diagnosis, Vd. According to RECIST, a Vt of more than 1.73Vd (20% increase in diameter) 
will be considered as progressive disease. For a tumor with doubling time shorter than 27 days 
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(SGR>2.6 %/d) and a treatment that completely blocks tumor growth, the drug will be 
considered without any effect and be categorized as progressive disease according to RECIST.  
 
Non-Hodgkin’s lymphoma patients response to therapy 
Estimated TR values of the applied treatment for the patients are shown in Table 5. Assuming a 
treatment that has only pure cytostatic effect, i.e. Vt=Vi, TR values were also calculated. Based 
on mean and standard deviation values from data in Table 5, frequency distribution of TR and 
LR were approximated with corresponding normal distribution with the same mean and 
standard deviation values. These distributions are shown in Fig.  11A-B for the observed TR and 
LR values as well as TR and LR values calculated for pure cytostatic treatment, respectively. 
 
Table 5) Treatment efficacy values for non-Hodgkin’s lymphoma patients treated with 
131
I labeled anti-
B1 antibody, retrieved from ref. (Sgouros, Squeri et al. 2003) and treatment efficacy calculated for a 
pure cytostatic treatment that can completely block tumor growth. 
Patient 
no. 
Treatment efficacy (observed) 
Treatment efficacy (calculated 
for a hypothetical pure 
cytostatic effect) 
TR LR 
Category 
according 
to RECIST 
TR LR 
Category 
according 
to RECIST 
1 2.65 0.73 SD 1.26 -0.31 SD 
2 7.42 2.56 PR 2.68 -0.79 PD 
3 5.15 1.00 SD 1.57 -0.79 PD 
4 4.451 2.4 PR 0.94 -0.24 SD 
5 2.80 1.39 PR 0.94 -0.16 SD 
6 4.50 -0.33 SD 2.83 -1.26 PD 
7 6.38 2.13 PR 1.42 -0.63 PD 
8 2.60 0.37 SD 1.26 -0.47 SD 
9 3.18 1.17 PR 1.10 -0.31 SD 
10 2.14 -0.46 SD 1.42 -0.79 PD 
11 4.52 0.32 SD 0 -0.94 PD 
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Figure 10)  Variation of the volume of a hypothetical exponentially growing tumor before and after 
treatment. TR=tumor response, LR=log-ratio measure for treatment effectiveness based on ref. (Karrison, 
Maitland et al. 2007), e1 and e2= underestimation of TR if pre-treatment or post-treatment growth of 
tumor is neglected, respectively. Err=overall underestimation of TR if pre-treatment and post-treatment 
growth of tumor are neglected (TR=LR+e1+e2).  
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Figure 11) A) Frequency distribution of TR and LR values based on the treatment results of 11 non-
Hodgkin’s lymphoma patients. The mean and standard deviation values were obtained from the 
sample and the corresponding normal distributions were drawn. TR: mean=4.16, standard 
deviation=1.69, LR: mean= 1.02, standard deviation=1.03. B) Frequency distribution of treatment 
efficacy for the same data as panel A by assuming that a treatment has only cytostatic effect. TR: 
mean=1.4, standard deviation=0.69. LR: mean= - 0.61, standard deviation=0.34. 
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Discussion 
SGR versus DT (Paper I, II) 
The results clearly show that selecting a proper variable for tumor growth rate is crucial. 
Recalculation of the previously published clinical data, as well as computer simulations and 
mathematical analysis, showed that quantitative analyses based on tumor growth rate can lead 
to erroneous and even contradictory results depending on the variable used for growth rate: 
SGR or DT. 
 
The quantity of tumor growth rate is used in a wide range of studies, e.g., when classifying 
tumors according to their growth rate (Arai, Kuroishi et al. 1994), or when the correlation 
between tumor growth rate with other factors is studied, e.g. patient survival (Balmukhanov, 
Turdugulov et al. 1982; Kuroishi, Tominaga et al. 1990; Arai, Kuroishi et al. 1994; Shiomi, 
Nishiguchi et al. 2001), radionuclide concentration in tumor (Duhaylongsod, Lowe et al. 1995; 
Shiomi, Nishiguchi et al. 2001), therapeutic effectiveness (Tsunoda, Shibusawa et al. 1992), and 
histological characteristics of tumor tissue (Lindell, Hartman et al. 2007). Furthermore, the 
results of all quantitative studies based on changes in growth rate may be different if 
parameters such as SGR and DT are used. To demonstrate such effects results based on 
published DT values were compared with those from calculated corresponding SGR values. 
These examples were selected, because the contradictory results of using SGR and DT could 
clearly be demonstrated. Otherwise, any set of tumor volume or tumor marker data collected 
at several time points can be selected to compare the results of quantitative analyses using DT 
and SGR. In general, the theoretical bases for the difference between DT and SGR are valid for 
any variable that might be measured with DT or SGR. 
 
SGR is the exponential tumor growth constant, which is the correct measure of tumor growth 
rate. SGR is least influenced by uncertainties of the measurement procedure and its frequency 
distribution is symmetric for an exponentially growing tumor, i.e. SGR is suitable for common 
statistical tests. When the growth rate of a tumor is measured with DT, the scale of 
measurement is nonlinearly transformed from the correct scale of SGR to the incorrect scale of 
DT (Eq. 6). The SGR of a tumor in clinical observations is in the order of a few tenths %/d to a 
few %/d. DT does not uniformly indicate the difference between growth rates of tumors 
throughout all ranges. In addition, DT does not have an absolute zero in its scale and DT is not 
defined when the growth rate is zero. Furthermore, the frequency distribution of DT (and log 
DT) is not symmetric, while most of the common statistical tests are based on the assumption 
of normally distributed variables.  
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Tumors may follow non-exponential growth model, e.g., the Gompertzian. Non-exponential 
growth models assume that the growth rate depends on time or size of tumor. The growth 
model of a non-exponentially growing tumor cannot be explained by a single value, and more 
parameters are needed to describe the true growth model of each tumor. As a result, the non-
exponential growth characteristics of tumors cannot be observed with only two volume 
measurements. In this work the difference between DT and SGR as quantities of tumor growth 
rate (at any time point or size) was studied. Therefore, the results are valid whether the growth 
rate is constant (exponential growth) or varying by time or size of tumor (non-exponential 
growth). However, non-exponential growth is not usually observed in natural growth of tumors 
in clinical studies, because the tumors can be followed only for a short time before the start of 
any treatment.  
 
Assuming that SGR is normally distributed the DT distribution will be positively skewed. This 
result is expected according to the nonlinear relationship between DT and SGR. It doesn’t mean 
that SGR is normally distributed in clinical observations, but the frequency distribution of SGR 
can represent the true distribution of growth rates of tumors (whether it is normal or not). 
Studies have shown that the frequency distribution of DT in clinical observations is positively 
skewed and the logarithmic transformation of DT is used by some researchers (Spratt and 
Spratt 1964; Spratt 1969; Shackney, McCormack et al. 1978; Balmukhanov, Turdugulov et al. 
1982; Kuroishi, Tominaga et al. 1990; Usuda, Saito et al. 1994). However, the logarithmic 
transformation cannot fully compensate for the asymmetry of DT distribution. Data on the real 
frequency distribution of SGR in clinical observations is not available, because DT has been the 
variable used for quantification of tumor growth rate so far. Furthermore, the true frequency 
distribution of tumor growth rate is not known in most studies and statistical approaches based 
on normal distribution of variable are used, e.g., Student’s t-test (Satkauskas, Batiuskaite et al. 
2005; Lee, Kim et al. 2008). Therefore, the same approach was used to compare groups of 
tumors both for SGR and DT, regardless of the distribution type of variables. This reveals 
another aspect of the importance of selecting a proper variable for tumor growth rate. 
Variations of tumor growth rate due to biological factors or measurement uncertainties are 
asymmetrically expressed by DT. DTm can thus correctly estimate the average growth rate of 
tumors only when the frequency distribution of DT is symmetric, i.e., when the uncertainty of 
growth rate estimation and the difference between the growth rates of tumors are relatively 
low. DTe is the only estimator that can give the true average growth rate of tumors. All 
measurement results, including negative SGR values, should be included in the calculation of 
mean SGR. It should be noted that the inclusion of negative values does not mean that such 
values must exist. Winer-Muram et al. observed the erroneous estimation of the average 
growth rate with DTm and made a better estimation by the reciprocal of the average of 
reciprocals of DT values (Winer-Muram, Jennings et al. 2002). The results of that method are 
comparable with those using SGR as growth rate parameter. 
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Differences in growth rates of tumors are mainly a result of different growth fractions, GF 
(fraction of tumor volume which consists of proliferating cells), and cell loss rates, CLR, i.e., the 
duration of cell cycle does not play a major role in the varying kinetics of tumor growth (Fingert, 
Campisi et al. 1993; Rew and Wilson 2000). Such a growth pattern can quantitatively be 
described using SGR. If the absolute value of CLR is added to the SGR of tumor volume, the SGR 
of the entire tumor in the absence of cell loss is obtained. The SGR of the proliferating cells can 
then be obtained by dividing the result by GF. In general, the volumetric SGR of a tumor with 
polyclonal cell population (a heterogeneous SGR distribution within the tumor) is the mean of 
SGR values weighted by the fraction of each cell component, including stromal and tumor cell 
populations, i.e., for a tumor with n cell components: V=V1+V2…+Vn, then 
V·SGRV=V1·SGR1+V2·SGR2…+Vn·SGRn. Similar to DTm within a population, calculation of 
volumetric growth rate of tumor as mean DT of its components will result in erroneous 
estimations of the growth rates. 
 
Tumor growth and dissemination in clinical studies (Paper III) 
The correlation between tumor doubling time and its volume is usually used in clinical studies, 
where the growth decline with tumor size is to be assessed (Nakamura, Roser et al. 2003; 
Ozono, Miyao et al. 2004). However, by definition this technique is not mathematically valid 
according to the Gompertzian growth model. The present study was thus based on the linear 
relationship between SGR and the logarithm of tumor volume according to the Gompertzian 
model. Our approach enabled us to estimate metastasis formation times and rates. Akanuma 
previously attempted to find the model constants for the Gompertzian growth model using the 
linear correlation between growth rate and the logarithm of tumor volume (Akanuma 1978). 
His method was based on a graphical estimation of SGR at different tumor volumes. Tumors 
were scaled according to their doubling time and very high or negative values were excluded. 
 
There are a number of non-exponential growth models available. In this work, only the 
Gompertzian growth model was evaluated because it is the most commonly adopted model in 
clinical studies (Bajzer 1999; Afenya and Calderon 2000). The approach is, however, 
theoretically applicable to any growth model.  
 
The results show that fitting of different growth curves to the volume of each tumor is not 
sufficient to estimate the true growth model of tumors, when the observation of tumor growth 
is limited in time, e.g. in clinical observations. In two patients, the growth of metastases was 
followed for several years, and still the direct curve fitting was insufficient to estimate the true 
growth model. It is also hazardous to extrapolate growth curves, because different growth 
models may converge during a short time period and then diverge. Estimations of tumor 
formation times or metastasis formation rates, based on extrapolations, can be largely 
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erroneous. The development of more precise quantitative approaches to retrieve all 
information from available clinical data is therefore crucial. A previous clinical study called for 
more accurate quantification of the growth rates of human cancer, providing data that is 
essential for understanding the biological variance of human cancers (Spratt, Meyer et al. 
1995). Variances in the observed growth rates of tumors of the same type either in one patient 
or in a population can be due to: (a) measurement uncertainties, (b) growth deceleration with 
increasing tumor volume, or (c) other biological differences between tumors. In this work a 
mathematically more correct approach was developed, compared to conventional methods, to 
analyze tumor growth in clinical studies. The results showed that for measurement of tumor 
growth rate at a specific time or volume, SGR is a more appropriate variable than DT, also when 
the variance was induced by measurement uncertainties (Paper I) or biological factors (Paper 
II).  
 
In Paper III the relation between SGR and the logarithm of tumor volume was used to assess 
the growth model of tumors in clinical studies. The growth model of groups of tumors of the 
same type either in one patient or in a group of patients was examined. A significant correlation 
between SGR and the logarithm of tumor volume in each group of tumors indicates that growth 
deceleration is an important factor in variances in the observed growth rates of tumors of the 
same type either in one patient or in a population. A general Gompertzian growth model might 
then estimate the growth of all tumors, i.e., the smaller tumors represent the growth of larger 
tumors when they were of small size and vice versa. Lack of correlation between SGR and the 
logarithm of tumor volume indicates that biological factors other than growth deceleration due 
to volume are more important in the variances in the observed growth rates of tumors of the 
same type either in one patient or in a population. These tumors may grow exponentially with 
different growth rates, or according to the Gompertzian model, but the model constants, SGR0 
and λ, may be distributed heterogeneously among the tumors. 
 
The correlation between SGR and the logarithm of tumor volume was statistically significant 
regarding the growth of meningiomas in a group of patients from the literature (Nakamura, 
Roser et al. 2003). Further analysis by dividing the material into small and large tumors also 
supported this result. A similar growth model observed for a group of patients with one tumor 
type corroborates that the response rate in this group is a suitable measure to assess the 
efficacy of novel therapeutics. The result from the second study of meningiomas (Nakasu, 
Fukami et al. 2005) was different with no significant correlation between SGR and the logarithm 
of tumor volume. 
 
According to the linear regression of tumor SGR with the logarithm of its volume, the growth of 
liver metastases in the carcinoid patient were described by a general growth model. This 
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patient was treated with octreotide. Since, based on curve fitting results, none of tumors in this 
patient deviate from exponential growth, the treatment was assumed to have no effect on 
growth of these tumors. The growth of lung metastases in the patient with renal cell carcinoma 
might biologically differ widely, but were still describable by a general growth model. Analysis 
of the metastasis formation rate showed that the estimated number of metastases was in line 
with such an interpretation. Carcinoid liver metastases probably grew according to a general 
Gompertzian growth model, while renal cancer metastases in the lungs probably grew 
exponentially with different growth rates. No evidence of non-exponential growth was 
observed. This result also highlights the need for careful interpretation of model fitting results. 
 
A higher metastasis formation rate in Fig. 9 does not necessarily mean a larger number of 
metastases at a time point, because the time origin in this figure is the time of the formation of 
the first metastasis, which is different for different models. A decelerating growth model, e.g. 
the Gompertzian model, implies a higher metastasis formation rate than the exponential 
model, but the number of metastases should be calculated for any specific time to compare 
different models. The estimated number of liver metastases in the patient with ileum carcinoid 
was 9 and 22 at the time of primary surgery using the exponential and the Gompertzian 
models, respectively. The value of 9 metastases is not realistic, since 24 metastases were 
imaged beside the studied metastases. The Gompertzian model thus provided the best 
estimate of the number of liver metastases. The estimated number of lung metastases in the 
patient with renal cell carcinoma was 14 and 84 at the time of primary surgery according to the 
exponential and the Gompertzian models, respectively. The value of 84 metastases is probably 
not realistic, since only one small, non-growing, metastasis was imaged beside the 7 lesions 
studied. If other metastases were present, they should have grown to visible size during 10 
years of follow-up. Here, the exponential model thus provided the best estimate of the number 
of lung metastases. Our results emphasize the importance of correct information on tumor 
growth to estimate the number and size distribution of metastases correctly. 
 
Tumor response to therapy (Paper IV) 
The presented quantity for objective assessment of solid tumor response to therapy, TR, is a 
general continuous measure regardless of the mechanism of the effect: cytotoxic and/or 
cytostatic. Studies have shown that tumor growth rate is a valuable parameter for, e.g., 
prediction of recurrence after surgery (Cucchetti, Vivarelli et al. 2005) and survival of patients 
(Blankenberg, Teplitz et al. 1995), and the change in tumor growth rate can serve as a surrogate 
end-point for determination of therapy response (Haney, Thompson et al. 2001). In this study, a 
simplified formula was derived based on the effect of therapy on kinetics of tumor growth. 
Tumor response was measured by the logarithm of the ratio of post-treatment tumor volume 
to the volume of tumor (at time of efficacy assessment) if therapy was not initiated. TR=0 
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indicates no effect and larger TR values distinguish more effective therapies from less effective 
ones. Negative TR value indicates post-treatment tumor swelling or increased growth rate.  
 
The log-ratio (LR) measure for tumor response to therapy, which was used by Kharison et al. 
(Karrison, Maitland et al. 2007) is calculated as the logarithm of the ratio of post-treatment 
tumor volume to the pre-treatment tumor volume. The natural growth of tumor between 
diagnosis and therapy initiation as well as after therapy is neglected in the LR value. There 
might be a few weeks or longer delay between tumor diagnosis and initiation of therapy due to 
practical limitations or necessity of further evaluations. Tumors continue to grow during this 
period. The volume of a tumor with doubling time of 70 days will increase 23% during a three 
week period. Repopulation of tumor cells during therapy is also an important factor that should 
not be neglected (Davis and Tannock 2000; Kim and Tannock 2005). TR values are thus larger 
than corresponding LR values for the same set of tumors. The overall under-estimation of 
treatment effectiveness by LR (Err) is larger for a rapidly growing tumor or when the time 
between pre-treatment and post-treatment volume assessments is long. The relative 
importance of Err also depends on the response effect level obtained, i.e., for a more effective 
treatment LR is less affected by this error.  
 
The generally used methods when comparing the post-treatment volume of tumor with the 
pre-treatment volume, e.g. in RECIST, will thus result in underestimation of treatment 
effectiveness. Analysis of the radionuclide therapy of Non-Hodgkin’s lymphoma patients 
showed that six of eleven patients would be categorized as having progressive disease, 
according to RECIST, if a pure cytostatic therapy that could completely block tumor growth was 
initiated. It has already been shown that RECIST underestimates the effect of imatinib on 
metastatic gastrointestinal stromal tumor (Choi, Charnsangavej et al. 2007). The fact that 
treatment effectiveness is underestimated by LR or RECIST has important implications on 
assessing the efficacy of new anticancer drugs or different combinations of therapies. 
 
The fact that clinical trial designs based on LR values are feasible was demonstrated (Karrison, 
Maitland et al. 2007), which suggests that TR can also be used for such studies. The main 
difference between TR and LR is the reference volume of tumor for efficacy assessment, which 
is the volume of corresponding untreated tumor or pre-treatment volume of tumor for TR and 
LR, respectively. Statistical aspects of using such continuous variables in clinical trials, e.g. 
handling extreme cases as complete disappearance of lesions are discussed elsewhere 
(Karrison, Maitland et al. 2007).  It is also noteworthy that any natural growth model can be 
used in the TR calculation (Eq. 17) when determining Vn.  
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The major limitation with TR, compared to LR, is the need of knowledge of the natural growth 
model and growth rate of the tumor. The natural growth rate can in theory be estimated 
before treatment initiation. In practice, treatment is usually initiated as early as possible after 
diagnosis. In the present study no such data was available and the growth rate was assumed to 
be the average re-growth rate of tumors after therapy, which in reality might be clearly 
different from the true growth rate of tumors before treatment. In this case, these data were 
used only for demonstration without any clinical interpretation of the results. If tumor volumes 
at two occasions prior to start of therapy are available, e.g. having two CT scans at diagnostic 
investigation and an investigation just before therapy initiation, natural SGR of tumor and 
consecutively Vn can be calculated. Taking both inter- and intra-operator as well as inter-scan 
variability into account, an increase of the measured volume by more than 25% is needed for a 
95% likelihood of being real growth rather than measurement inaccuracy. For an exponentially 
growing tumor increase of the measured volume will be more than 25% if the measurement 
time interval between two investigations is longer than 0.32 DT. If tumor volume prior to 
treatment is only available at one occasion, e.g. the first diagnostic imaging, tumor volume at 
time of therapy initiation can be estimated by back-extrapolation of volume regression curve 
during therapy, which might be described by exponential model (Stein, Figg et al. 2008). That 
measure together with the first tumor volume available can be used for estimation of the 
natural SGR of tumor.  
 
Tumor structure can be rather non-homogenous consisting of, e.g., different clones of cancer 
cells (with different sensitivities to an anticancer agent), stroma, and necrotic areas. The value 
of SGR of a tumor may thus be obtained from the spatial distribution of SGR values within the 
tumor: 
 
 
V
dzdydxz)y,sgr(x,
V
1
SGR ,    (20) 
 
where sgr(x,y,z) is for each part of tumor and SGR is for tumor volume. An effective treatment 
can reduce sgr(x,y,z) differently in different parts of the tumor depending on, e.g., 
pharmacokinetics and dose response of a systemically used agent. This will accordingly cause a 
reduction in SGR of tumor as was used in the presented model (Eq. D). Studies have shown that 
functional imaging variables might be correlated with tumor growth rate, e.g. using PET 
(Duhaylongsod, Lowe et al. 1995; Tann, Sandrasegaran et al. 2008). Further developments in 
this field may facilitate tumor SGR estimation by a functional imaging before treatment and 
also integration of TR based anatomical changes in tumor into other means of tumor response 
assessment by functional imaging with MRI (Chenevert, McKeever et al. 1997) or PET 
(Stroobants, Goeminne et al. 2003; Boss, Olmos et al. 2008). 
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Conclusions 
Quantification of the volumetric growth rate of tumor using doubling time can give very 
different results compared to using the specific growth rate, which is a correct quantity for 
tumor growth rate. The average growth rate of tumors must also be estimated by the mean 
SGR or its equivalent doubling time. The uncertainty of SGR can be reduced with increasing 
measurement time interval, or decreasing volume measurement uncertainties. In addition, SGR 
is a suitable parameter for common statistical testing based on the assumption of normally 
distributed parameters. This conclusion is also valid for determination of the increase rate of 
tumor marker level, whether it is correlated with the growth rate of tumor volume or not. 
 
With limited measurements available in clinical studies fitting of different growth curves to the 
data is not sufficient to estimate the true growth model of tumors. Analysis of the correlation 
between growth rate and the volume of tumor may give better estimate of tumor growth 
model for some types of tumors. Formation times and formation rates of metastases may also 
be estimated by the linear regression of SGR with the logarithm of tumor volume. 
 
Available criteria for assessment of tumor response to therapy, including RECIST, neglect 
natural growth rate of tumor, which leads to underestimation of treatment effectiveness. 
Logarithm of the ratio between treated tumor volume and the volume of corresponding non-
treated tumor is a general continuous quantity for tumor response, useful for both cytostatic 
and cytotoxic treatments. The concept may also accommodate integration of anatomical 
changes of tumor into changes in other biological characteristics of tumor after therapy. 
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Further studies 
 
This work can be categorized as translational research, where basic theory is directly applied to 
patient related data. It ended up with a new framework for quantitative studies in clinical 
settings rather than conclusive interpretations based on the presented clinical data. The results 
will hopefully lead to enhanced use of frequency distributions of SGR, and studies of correlation 
between SGR and different variables, e.g., different tumor markers levels or tumor volume, 
based on larger number of patient data to facilitate decisive interpretations in clinical studies. 
However, for future formulations based on SGR, it must be noted that SGR is a mathematical 
concept that can be virtually calculated and the absolute relative growth rate of tumor 
approaches SGR when the measurement time interval approaches zero. While %/d is 
appropriate for tumor growth rate in clinical settings, %/h or %/min are more appropriate for 
more rapidly growing tumors, e.g., in animal models or cell culture, respectively. 
 
An interesting feature of SGR is its capability for future multiscale modelings, where data on, 
e.g., cellular heterogeneities within tumor quantified with, e.g., functional imaging (SPECT, PET 
or MRI), can be linked to volumetric changes of tumor. Anatomical and functional means of 
evaluation of tumor response to therapy can also be integrated within such models. 
 
Tumor response, TR, measure formulated in this work can be used for future clinical trials on 
novel, or combinations of, anticancer therapeutic modalities. Accurate measure of TR facilitates 
a more correct evaluation of therapeutic efficacy in correlation with other variables, e.g., tumor 
size or growth rate and patient survival.  
 
TR is the measure of the effect of therapy on natural growth of tumor. However, the same 
approach can be used for evaluation of the effect of any other factor that may influence the 
tumor growth e.g., the function of the immune system. 
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